Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
Full metadata record
|dc.identifier.citation||Diabetes Therapy, 2013; 4(1):51-66||-|
|dc.description.abstract||INTRODUCTION It is unclear as to whether human or long-acting analog insulins represent the most efficient use of health and non-healthcare resources in the management of type 2 diabetes mellitus (T2DM). The aim of this study was to evaluate the value for money relationship associated with the use of these insulins in the UK setting. METHODS A literature search was performed for studies reporting expenditure associated with the use of human and analog insulins. Data from this review informed a budget impact assessment model. Costs were converted to a common currency and results are reported in 2011 British pounds sterling (GBP) values. RESULTS Annual diabetes-related medication expenditure and patients total expenditure associated with the management of T2DM were estimated to be £397 million and £3,901 million, respectively. Substitution of human insulin for analog insulins was associated with a drug acquisition cost saving of between £5 million and £23 million each year. Overall, though, total expenditure increased significantly with increased use of human insulin by £34 million to £136 million each year depending on the degree of substitution. CONCLUSIONS On the face of it, analog insulins are more expensive, prompting questions about potential cost savings to health services in the UK from direct substitution to the less expensive human preparation. The current analysis illustrates that the increased use of human insulin and decreased use of analog insulin would, however, increase the overall net societal cost of managing insulin-treated patients with T2DM. Governments and decision makers should consider that total healthcare expenditure would not necessarily fall when decisions are based solely on the use of cheaper products.||-|
|dc.description.statementofresponsibility||Jason Gordon, Marc Evans, Phil McEwan, Steve Bain, Jiten Vora||-|
|dc.publisher||Springer Healthcare Communications Ltd||-|
|dc.rights||© The Author(s) 2013. This article is published with open access at Springerlink.com||-|
|dc.subject||Costs and cost analysis||-|
|dc.subject||Type 2 diabetes||-|
|dc.title||Evaluation of insulin use and value for money in type 2 diabetes in the United Kingdom||-|
|Appears in Collections:||Aurora harvest|
Public Health publications
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.